#459: George Goldsmith on Improving Mental Health

— George Goldsmith's career arc spans technology, healthcare governance, and regulated industries, culminating in co-founding Compass Pathways to develop psilocybin therapy for depression.

— Depression affects over 300 million people worldwide; approximately 30% do not respond to traditional antidepressants, leaving roughly 100 million people with treatment-resistant depression suffering unnecessarily.

— Psilocybin appears to reset neural networks associated with rumination and negative thought patterns by disrupting the brain's "default mode network," offering potential relief where conventional medicines fail.

— Compass's clinical protocol involves weeks of antidepressant tapering, psychological preparation, a guided psilocybin session with therapists present, and structured follow-up debriefing to ensure safety and personalization.

— Regulation exists to protect vulnerable populations by ensuring medicines have rigorous safety and efficacy data; Compass deliberately sets the highest standards globally to enable responsible scale and reimbursement.

— The company's vision extends beyond single-dose therapy to a personalized, predictive, preventive model: understanding who benefits, predicting relapse risk, and preventing recurrence through ongoing support and data integration.

— If you or a loved one has failed multiple antidepressants, emerging psilocybin-assisted therapy in regulated clinical trials may represent a legitimate medical option worth exploring as research advances toward approval.

— Compass Pathways is pursuing a public company transparency model and stakeholder-focused governance; monitoring their clinical trial data releases and regulatory milestones can signal when psilocybin therapy becomes accessible through insurance reimbursement rather than out-of-pocket only.